Insulin Lispro市場：按Insulin Lispro產品類型、按適應症、按年齡層、按藥物類別、按配銷通路、按地區

Insulin Lispro Market, By Product Type of Insulin Lispro, By Indication, By Age Group, By Drug Class (Humalog, Admelog and Other brands), By Distribution Channel, By Geography

出版日期: 2023年10月30日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年全球Insulin Lispro市場規模為73.2億美元，預計2030年將達111.5億美元，2023年至2030年年複合成長率為6.2%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	73.2億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	6.20%	2030年市場規模預測	111.5億美元

圖 1.Insulin Lispro全球市場佔有率(%)（按地區），2023 年

Insulin Lispro用於治療需要胰島素治療的第 1 型糖尿病（身體不會產生胰島素且無法控制血液中糖含量的疾病）。始終與其他類型的胰島素一起使用，除非與外部胰島素幫浦一起使用。Insulin Lispro注射產品也用於改善第 2 型糖尿病成人患者的血糖控制，這些患者僅對口服藥物反應不佳。Insulin Lispro是一種類似胰島素，與人類胰島素的不同之處在於兩個胺基酸序列：B-28 處的脯胺酸和 B-29 處的離胺酸。這種修飾可防止胰島素形成二聚體和六聚體，這些二聚體和六聚體的活性低於單體胰島素。Insulin Lispro給藥後吸收迅速，2～4小時內達到峰值，並持續有效18～30小時。

市場動態：

近年來，全球Insulin Lispro市場顯著成長，主要得益於糖尿病患者數量的增加以及胰島素輸送設備領域的技術進步。這一成長預計將得到政府措施的增加、患者對胰島素需求的增加以及已開發國家有利的醫療報銷政策等因素的進一步支持。由於久坐習慣和不健康飲食習慣等生活方式的改變，全球罹患糖尿病的人數不斷增加。根據國際糖尿病聯盟統計，2021年約有5.37億成年人患有糖尿病，預計2030年這數字將增加至6.43億，2045年將增加至7.84億。肥胖率的增加和久坐的生活方式是糖尿病病例增加的主要原因。然而，胰島素類似物製劑的高成本和生物相似藥製劑的可用性對市場成長構成了挑戰。從積極的一面來看，積極的政府配合措施和新興市場醫療保健服務的改善正在為該市場的參與者創造利潤豐厚的機會。類似胰島素輸送裝置和製劑的開發也可能塑造未來的動態。

本研究的主要特點

本報告對全球Insulin Lispro市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、業績和策略等參數，介紹了全球Insulin Lispro市場的主要企業。
該報告的見解使行銷人員和經營團隊負責人就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的資訊。
全球Insulin Lispro市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球Insulin Lispro市場的各種策略矩陣，將有助於相關人員做出決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 7.32 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	6.20%	2030 Value Projection:	US$ 11.15 Bn

Insulin lispro is used to treat type 1 diabetes (a condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used with an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remaining effective for 18-30 hours.

Market Dynamics:

The global insulin lispro market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries. Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. As per the International Diabetes Federation, approximately 537 Mn adults were living with diabetes in 2021, and this number is expected to rise to 643 Mn by 2030 and 784 Mn by 2045. The increasing obesity rates and sedentary lifestyles have significantly contributed to this rise in diabetes cases. However, the high costs of insulin analogs and the availability of biosimilar alternatives remain a challenge for market growth. On the positive side, favorable government initiatives and improved access to healthcare services in developing nations present lucrative opportunities for players operating in this market. Developments in analog insulin delivery devices and formulations will also likely shape the future dynamics.

Key features of the study:

This report provides in-depth analysis of the global insulin lispro market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global insulin lispro market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Gan & Lee Pharmaceuticals and Ypsomed AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market

Detailed Segmentation:

By Product Type
- Insulin Lipro pre-filled pen
- Insulin lispro solution vials
- Insulin lispro solution cartridge
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Others
By Age Group
- Pediatric Patients
- Adult Patients
- Geriatric Patients
By Drug Class
- Humalog (Eli Lilly and Company)
- Admelog (Sanofi)
- Other brands
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- Merck & Co., Inc.
- Pfizer Inc.
- F.Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- Johnson & Johnson Services, Inc.
- Biocon Limited
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Wockhardt Ltd.
- Lupin Pharmaceuticals, Inc.
- Bioton S.A.
- Gan & Lee Pharmaceuticals
- Ypsomed AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Insulin Lispro, By Product Type of Insulin Lispro
- Market Insulin Lispro, By Indication
- Market Insulin Lispro, By Age Group
- Market Insulin Lispro, By Drug Class
- Market Insulin Lispro, By Distribution Channel
- Market Insulin Lispro, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Growing prevalence of diabetes
- Restrains
Decline in demand for insulin during Covid-19 pandemic
- Opportunities
Growing launch of new product
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Insulin Lispro Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Insulin Lispro Market , By Product Type of Insulin Lispro, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Insulin Lipro pre-filled pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Insulin lispro solution vials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Insulin lispro solution cartridge
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

6. Insulin Lispro Market , By Indication, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

7. Insulin Lispro Market , By Age Group, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Paediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

8. Insulin Lispro Market , By Drug Class, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Humalog (Eli Lilly and Company)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Admelog (Sanofi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Other Brands
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

9. Insulin Lispro Market , By Distribution Channel, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

10. Insulin Lispro Market , By Region, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2023 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)

11. Competitive Landscape

Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
Novo Nordisk A/S
Merck & Co., Inc.
Pfizer Inc.
Hoffmann-La Roche Ltd.
AstraZeneca PLC
Johnson & Johnson Services, Inc.
Biocon Limited
Mylan N.V.
Boehringer Ingelheim International GmbH
Wockhardt Ltd.
Lupin Pharmaceuticals, Inc.
Bioton S.A.
Gan & Lee Pharmaceuticals, Inc.
Ypsomed AG
Analyst Views